Viventia Biotech Inc., Merck KGaA deal

MRK’s Biovation Ltd. unit (Aberdeen, U.K.) will apply its DeImmunisation technology to a cytotoxic VBI protein, for use in treating cancer. DeImmunisation technology is designed to eliminate or reduc...